Php100 - Utilizations and Expenditures of Tumor Necrosis Factor Antagonists in Medicare Part D: Cross- Sectional Study (2014-2015)

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.994
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pre-Medicare Eligible Individuals' Decision-Making in Medicare Part D: An Interview Study

INNOVATIONS in pharmacy
2010English

The Response of Drug Expenditures to Non-Linear Contract Design: Evidence From Medicare Part D

2013English

Gabepentinoids and Benzodiazepines in Medicare Part D

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

No Impact of Tumor Necrosis-Factor Antagonists on the Joint Manifestations of Sarcoidosis

International Journal of General Medicine
Medicine
2013English

Tumor Necrosis Factor Α Antagonists in the Treatment of the Patients With Rheumatoid Arthritis

Reumatologia
RheumatologyAllergyImmunology
2012English

Tumor Necrosis Factor

2004English

Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries

Journal of General Internal Medicine
Internal Medicine
2018English

Proportion of Decedents’ Expenditures Among Recent Reductions in Medicare Expenditures

JAMA Internal Medicine
Internal Medicine
2018English

Lethal Toxicity of Lipopolysaccharide and Tumor Necrosis Factor in Normal and D-Galactosamine-Treated Mice

Journal of Experimental Medicine
MedicineAllergyImmunology
1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy